26
|
Hanlon I, Hewitt C, Bell K, Phillips A, Mikocka-Walus A. Systematic review with meta-analysis: online psychological interventions for mental and physical health outcomes in gastrointestinal disorders including irritable bowel syndrome and inflammatory bowel disease. Aliment Pharmacol Ther 2018; 48:244-259. [PMID: 29901820 DOI: 10.1111/apt.14840] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2018] [Revised: 04/08/2018] [Accepted: 05/17/2018] [Indexed: 12/19/2022]
Abstract
BACKGROUND Online psychotherapy has been successfully used as supportive treatment in many chronic illnesses. However, there is a lack of evidence on its role in the management of gastrointestinal (GI) diseases. AIMS To examine whether online psychological interventions improve mental and physical outcomes in gastrointestinal diseases. METHODS We searched CINAHL Plus, MEDLINE, EMBASE, Health Management Information Consortium, PsycINFO, British Nursing Index, Cochrane Library, a specialised register of the IBD/FBD Cochrane Group, MEDLINE (PubMed) WHO International Clinical Trial Registry, ClinicalTrials.gov, and reference lists of all papers included in the review. The Cochrane Risk of Bias Tool was used to assess internal validity. Where possible, data were pooled using random-effects meta-analysis. RESULTS We identified 11 publications (encompassing nine studies) meeting inclusion criteria. One study had a high risk of selection bias (allocation concealment), all studies had a high risk of performance and detection bias. Eight studies were included in the meta-analyses (6 on irritable bowel syndrome [IBS] and two on inflammatory bowel disease [IBD]). Online cognitive behavioural therapy (CBT) was shown to significantly improve gastrointestinal symptom-specific anxiety (MD: -8.51, 95% CI -12.99 to -4.04, P = 0.0002) and lessen symptom-induced disability (MD: -2.78, 95% CI -5.43 to -0.12, P = 0.04) in IBS post intervention. There was no significant effect of online CBT on any other outcomes in IBS. No significant effect of online psychotherapy was demonstrated in IBD. CONCLUSION There is insufficient evidence to demonstrate the effectiveness of online CBT to manage mental and physical outcomes in gastrointestinal diseases.
Collapse
|
27
|
Xu C, Guo H, Wang Q, Qu P, Bell K, Chen J. Interaction of obesity with smoking and inflammatory arthropathies increases the risk of periprosthetic joint infection: a propensity score matched study in a Chinese Han population. J Hosp Infect 2018; 101:222-228. [PMID: 29966755 DOI: 10.1016/j.jhin.2018.06.017] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Accepted: 06/19/2018] [Indexed: 12/23/2022]
Abstract
BACKGROUND Although a large number of studies have identified obesity as an independent risk factor for the development of periprosthetic joint infection (PJI), the synergistic impacts of obesity with other factors on PJI remain unknown. Additionally, few studies have specifically explored the risk factors of PJI within a Chinese population. AIMS To investigate the association between obesity and PJI in a Chinese population, and identify synergistic impacts of obesity with other risk factors on the development of PJI. METHODS Three hundred and seven patients at a single institution with a diagnosis of PJI following primary total hip or knee arthroplasty, treated from 2008 to 2015, were identified. Each case was matched with two controls who did not develop PJI after primary total hip or knee arthroplasty in the study period using propensity score matching for several important parameters. Multi-variable logistic regression models were used to estimate the association between body mass index (BMI) and the risk of developing PJI. Interaction and stratified analyses were conducted according to age, sex, type of surgery, smoking status, alcohol use, diabetes, inflammatory arthritis, liver disease and renal disease. FINDINGS The multiple logistic analyses showed that obesity was associated with increased risk of PJI [odds ratio (OR) 2.48; 95% confidence interval (CI) 1.66-3.69]. When analysed as a continuous variable, BMI was also associated with increased risk of PJI (OR per 1 kg/m2 increase in BMI 1.08; 95% CI 1.02-1.14). In the interaction analysis, patients who were obese and smoked had a higher OR of developing PJI than non-smokers who were obese (OR 3.54 vs 1.55, P-value for interaction=0.031). Similarly, the OR was much higher for patients with both obesity and inflammatory arthritis than for patients who were obese with no history of inflammatory arthritis (OR 3.9 vs 1.55, P-value for interaction=0.029). No other significant interactions were found in the association between obesity and PJI. CONCLUSION Obesity is an independent risk factor for the development of PJI in the Chinese Han population. Surgeons should be aware that obese patients who smoke or have inflammatory arthritis are at additional increased risk of PJI.
Collapse
|
28
|
Bone C, Eysenbach L, Bell K, Barry DT. Our Ethical Obligation to Treat Opioid Use Disorder in Prisons: A Patient and Physician's Perspective. THE JOURNAL OF LAW, MEDICINE & ETHICS : A JOURNAL OF THE AMERICAN SOCIETY OF LAW, MEDICINE & ETHICS 2018; 46:268-271. [PMID: 30146992 DOI: 10.1177/1073110518782933] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
The opioid epidemic has claimed the lives of more than 183,000 individuals since 1999 and is now the leading cause of accidental death in the United States. Meanwhile, rates of incarceration have quadrupled in recent decades, and drug use is the leading cause of incarceration. Medication-assisted treatment or MAT (i.e. methadone, buprenorphine) is the gold standard for treatment of opioid use disorder. Incarcerated individuals with opioid use disorder treated with methadone or buprenorphine have a lower risk of overdose, lower rates of hepatitis C transmission, and lower rates of re-incarceration. Despite evidence of improved outcomes, many jails and prisons do not offer MAT to individuals with opioid use disorder. This seems partly due to a scientifically unjustified preference for an abstinence-only treatment approach. The absence of MAT in prisons and jails results in poor outcomes for individuals and poses a public health threat to communities. Furthermore, it disproportionately harms poor communities and communities of color. Health care providers in prisons and jails have an ethical obligation to offer MAT to individuals with opioid use disorder to mitigate risk of infectious diseases, opioid overdose and health disparities associated with incarceration.
Collapse
|
29
|
Linden M, Marullo S, Bone C, Barry DT, Bell K. Prisoners as Patients: The Opioid Epidemic, Medication-Assisted Treatment, and the Eighth Amendment. THE JOURNAL OF LAW, MEDICINE & ETHICS : A JOURNAL OF THE AMERICAN SOCIETY OF LAW, MEDICINE & ETHICS 2018; 46:252-267. [PMID: 30146987 DOI: 10.1177/1073110518782926] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
This article argues that correctional institutions violate the Eighth Amendment when they refuse to establish MAT programs and prevent doctors from exercising medical judgment to properly treat incarcerated people with OUD.
Collapse
|
30
|
Momirovski D, Tian P, Bell K, Pepe S, Elwood N. Characterisation of SIRPα + cells in umbilical cord blood. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
31
|
Ricketti P, Schwartz D, Calero K, Anderson W, Diaz-Sein C, Rechkemmer M, Bell K, Dahdad M, Nakase-Richardson R. 1031 A Multicenter Study Examining Two Scoring Algorithms for Diagnosis of Obstructive Sleep Apnea (OSA) in an Acute Neurorehabilitation Population with Traumatic Brain Injury (TBI). Sleep 2018. [DOI: 10.1093/sleep/zsy061.1030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
32
|
Bell K, Kobayshi I, Mellman T. 0150 Perceived Racism and Nocturnal Heart Rate Variability in Urban-Residing African Americans. Sleep 2018. [DOI: 10.1093/sleep/zsy061.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Chrysostomou V, Hatch RJ, Colgan T, Paul JP, van Wijngaarden P, Trounce I, Lopez Sanchez MIG, Bell K, Grus F, Crowston JG. Visuelle Regeneration als Ziel für das Glaukom. Ophthalmologe 2018; 116:14-17. [DOI: 10.1007/s00347-018-0649-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Siebelt L, McFadden A, Jackson C, Bell K, Atkin K, Innes N, Jones H, MacGillivray S. Consultation on Gypsy, Traveller and Roma people's engagement and trust in healthcare. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx189.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
35
|
Hashmi F, Fairhurst C, Cockayne S, Cullen M, Bell K, Coleman E, Harrison‐Blount M, Torgerson D. The
EV
erT2 (Effective Verruca Treatments 2) trial: a randomized controlled trial of needling vs. nonsurgical debridement for the treatment of plantar verrucae. Br J Dermatol 2017; 177:1285-1292. [DOI: 10.1111/bjd.15751] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/15/2017] [Indexed: 11/29/2022]
|
36
|
Bell K, Wilding C, Beck S, Pfeiffer N, Grus F. Neurotrophins involved in neuroprotective antibody effect. Acta Ophthalmol 2017. [DOI: 10.1111/j.1755-3768.2017.03522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Dueland S, Valle J, Bell K, Faluyi O, Staiger H, Gjertsen T, Møller AS, Aksnes AK, Palmer D. TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.053] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
McColl KA, Sunarto A, Slater J, Bell K, Asmus M, Fulton W, Hall K, Brown P, Gilligan D, Hoad J, Williams LM, Crane MSJ. Cyprinid herpesvirus 3 as a potential biological control agent for carp (Cyprinus carpio) in Australia: susceptibility of non-target species. JOURNAL OF FISH DISEASES 2017; 40:1141-1153. [PMID: 28026008 DOI: 10.1111/jfd.12591] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Revised: 10/20/2016] [Accepted: 10/21/2016] [Indexed: 06/06/2023]
Abstract
Carp (Cyprinus carpio L.) is a pest species in Australian waterways, and cyprinid herpesvirus 3 (CyHV-3) is being considered as a potential biological control (biocontrol) agent. An important consideration for any such agent is its target specificity. In this study, the susceptibility to CyHV-3 of a range of non-target species (NTS) was tested. The NTS were as follows: 13 native Australian, and one introduced, fish species; a lamprey species; a crustacean; two native amphibian species (tadpole and mature stages); two native reptilian species; chickens; and laboratory mice. Animals were exposed to 100-1000 times the approximate minimum amount of CyHV-3 required to cause disease in carp by intraperitoneal and/or bath challenge, and then examined clinically each day over the course of 28 days post-challenge. There were no clinical signs, mortalities or histological evidence consistent with a viral infection in a wide taxonomic range of NTS. Furthermore, there was no molecular evidence of infection with CyHV-3, and, in particular, all RT-PCRs for viral mRNA were negative. As a consequence, the results encourage further investigation of CyHV-3 as a potential biocontrol agent that is specific for carp.
Collapse
|
39
|
Kettle JG, Su Q, Grimster N, Kawatkar S, Throner S, Woessner R, Chen H, Bebernitz G, Bell K, Anderson E, Ruston L, Winter-Holt J, Lyne P, Vasbinder M, Chuaqui C. Abstract 979: Discovery of the JAK1 selective kinase inhibitor AZD4205. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-979] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Janus kinases are a family of four enzymes; JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2) that are critical in cytokine signalling, with constitutive activation of JAK/STAT pathways associated with a wide variety of malignancies. Elevated JAK/STAT signalling leading to increased activation of STAT3 is reported in a wide variety of cancers, including breast, liver, prostate, colorectal, head and neck, oesophageal, pancreatic, bladder, and non-small cell lung, and is implicated in the pathogenesis of diffuse large B-cell lymphoma and nasopharyngeal carcinomas. Overall, up to 70% of human tumours are linked to persistent elevated STAT3 activity which can be associated with poorer prognosis in many of these settings. In addition, elevated pSTAT3 is observed in response to chemotherapy treatment, and also in response to treatment with inhibitors of oncogenic signalling pathways such as EGFR, MAPK and AKT, and is associated with resistance or poorer response to agents targeting these pathways. In many of these cases, JAK1 is believed to be a primary driver of STAT3 phosphorylation and signalling, suggesting inhibition of JAKs as a therapeutic approach to treat these potential resistance mechanisms. The mixed JAK1/2 kinase inhibitor ruxolitinib is approved for the treatment of myeloproliferative neoplasms including intermediate or high risk myelofibrosis and polycythemia vera and has been tested in a variety of tumor settings. Since JAK2 is essential for the signal transduction downstream of erythropoietin, thrombopoietin and related receptors that control erythrocyte and megakaryocyte expansion, dosing of inhibitors that target JAK2 can be limited by toxicities such as thrombocytopenia and anaemia.
Starting from a non-kinome selective screening hit, structure-based design was used to optimise a series of aminopyrimidines that led to JAK1-selective candidate drug AZD4205. This compound demonstrates ATP competitive binding with IC50’s in a high ATP concentration enzyme assay against JAK1 of 73 nM (Ki = 2.8 nM), with high selectivity against JAK2 and JAK3 with IC50’s of 13,233 nM and >30,000 nM respectively. In addition it showed potent inhibition of p-STAT3 in a cell based assay of JAK1 activity with an IC50 of 128 nM and excellent selectivity across the kinome. In summary, AZD4205 is a highly potent JAK1-selective kinase inhibitor with excellent preclinical pharmacokinetics with potential for further clinical development. The optimization from screening hit to first disclosure of this candidate drug will be presented.
Citation Format: Jason G. Kettle, Qibin Su, Neil Grimster, Sameer Kawatkar, Scott Throner, Richard Woessner, Huawei Chen, Geraldine Bebernitz, Kristen Bell, Erica Anderson, Linette Ruston, Jon Winter-Holt, Paul Lyne, Melissa Vasbinder, Claudio Chuaqui. Discovery of the JAK1 selective kinase inhibitor AZD4205 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 979. doi:10.1158/1538-7445.AM2017-979
Collapse
|
40
|
Qin L, Orme M, Varol N, Kalkan A, Erdmann M, Bell K, Mukherjee J, Marbach S. Kombination von DPP-4-/SGLT-2-Inhibitoren als Add-on zu Metformin bei Patienten mit Typ-2-Diabetes: Vergleich mit OAD, GLP-1RA und Basalinsulin. DIABETOL STOFFWECHS 2017. [DOI: 10.1055/s-0037-1601751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
41
|
Jagoda P, Ziegenhain F, Bell K, Dzierma Y, Bücker A, Minko P. Etablierung eines Niedrigdosis-Abdomen-CT Protokolls anhand eines Schweinemodells und Alderson Phantoms mit einem Dual-Source-CT-Scanner der dritten Generation. ROFO-FORTSCHR RONTG 2017. [DOI: 10.1055/s-0037-1600433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
42
|
Bell K. HIV Prevention in Brazil. CLINICAL SOCIAL WORK AND HEALTH INTERVENTION 2016. [DOI: 10.22359/cswhi_7_4_05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
43
|
Wilmoth K, LoBue C, Clem M, Didehbani N, Hart J, Womack K, Bell K, Batjer H, Cullum C. B-72Reliability of Self-Reported Concussion History in Older Adults with and Without Cognitive Impairment. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw043.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Wilmoth K, LoBue C, Clem M, Didehbani N, Hart J, Womack K, Bell K, Batjer H, Cullum C. Traumatic Brain Injury -4Reliability of Self-Reported Concussion History in Older Adults with and Without Cognitive Impairment. Arch Clin Neuropsychol 2016. [DOI: 10.1093/arclin/acw042.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Liu X, Marder K, Stern Y, Dooneief G, Bell K, Todak G, Joseph M, Elsadr W, Williams JB, Ehrhardt A, Stein Z, Mayeux R. Gender Differences in HIV-Related Neurological Progression in a Cohort of Injecting Drug Users Followed for 3.5 Years. ACTA ACUST UNITED AC 2016; 1:17-30. [PMID: 16873176 DOI: 10.1300/j128v01n04_03] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
We evaluated potential gender differences in the development of HIV related neurologic impairment, by matching 38 pairs of HIV positive male and female injecting drug users on their baseline age, education, disease stage and CD4 counts, and following them for 3.5 years. Adjusting for age, education, drug use, history of head injury and baseline CD4 count, more women had sensory abnormalities and symptoms than men at baseline, but the odds of having neurological impairment, particularly extrapyramidal signs and sensory abnormalities were increased over time in men but not in women. Men with ARC or AIDS had more neurological impairment than women in similar stages of illness. This study suggests further investigations of gender differences in HIV disease progression.
Collapse
|
46
|
Dzierma Y, Bell K, Nuesken F, Palm J, Fleckenstein J, Licht N, Rübe C. EP-1672: mARC vs. IMRT treatment of prostate and head-and-neck cancer with flat and FFF energies. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32923-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
47
|
Dzierma Y, Bell K, Ames E, Nuesken F, Licht N, Rübe C. EP-1609: CBCT and planar imaging dose for prostate and head-&-neck patients using 3 different imaging systems. Radiother Oncol 2016. [DOI: 10.1016/s0167-8140(16)32860-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Goletzke J, Atkinson FS, Ek KL, Bell K, Brand-Miller JC, Buyken AE. Glycaemic and insulin index of four common German breads. Eur J Clin Nutr 2016; 70:808-11. [DOI: 10.1038/ejcn.2016.9] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Revised: 12/22/2015] [Accepted: 01/13/2016] [Indexed: 11/10/2022]
|
49
|
Raska P, Ott MA, Steele A, Bailey A, Hickman D, Allen D, Urbanek D, Glass K, Bailey J, Bell K, Montero A, Abraham J. Abstract P6-12-08: Healthcare barrier profiles in patients navigated for cancer screening and treatment and the impact of the affordable care act. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-12-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The underserved community experiences barriers to cancer screening that result in overall greater mortality rates across all cancers. Insurance coverage brought forth by the Affordable Care Act has the potential to significantly impact these barriers through reducing the burden of health care cost on the patient. In this study the authors observe the impact of the Affordable Care Act on the barrier profiles presented by the patients navigated for cancer screening and treatment.
Methods: Patient navigation encounters were recorded for a total of 1146 patients navigated for cancer screening and treatment at the Cleveland Clinic Foundation from the years 2012 through 2015. A total of 3259 encounters were classified into barrier types. Health care billed encounters were retrieved from EPIC for this group of patients from the time they entered patient navigation and classified in terms of insurance coverage. Patients were categorized according to their barrier profile. Appropriate generalized linear regression models were used to test for association of these profiles to number and types of navigation and health care encounters and cost, and to test for change in types of encounters and patient barrier profiles through time.
Results: The insurance barrier is present in 23% of all navigation encounters. Patients presenting with an insurance barrier had a greater mean number of navigation (p<0.001) and health care encounters (p<0.006), had a greater proportion of self-paid health care encounters (p<0.001) and a lower total cost billed for health care encounters after controlling for number of encounters (p<0.001) . The access barrier is present in 53% of navigation encounters while patients that present with only the access barrier account for 42% of the entire sample. Patients that present with only the access barrier have doubled every year (OR 2.2 per year, 95% CI [1.8 2.6]) from 2012 to 2015, while the proportion of self-paid health care encounters (OR 0.26 per year, 95% CI [0.25 0.28]) and the presence of the insurance barrier (OR 0.55 per year, 95% CI [ 0.49 0.62]) have more than halved during this time period.
Conclusion: Although the Affordable Care Act has clearly had an impact by lowering the number of insurance barrier navigation encounters through time, it has uncovered access as the predominant remaining barrier. Understanding and targeting the access barrier will be the most effective way to potentiate the effects of the ACA on patients being navigated for cancer screening and treatment.
Citation Format: Raska P, Ott MA, Steele A, Bailey A, Hickman D, Allen D, Urbanek D, Glass K, Bailey J, Bell K, Montero A, Abraham J. Healthcare barrier profiles in patients navigated for cancer screening and treatment and the impact of the affordable care act. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-12-08.
Collapse
|
50
|
Ferguson G, Deihl T, Bell K, Chang J. “I Don’t want that up in me”: patient conceptions of foreign body contraceptives. Contraception 2015. [DOI: 10.1016/j.contraception.2015.06.192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|